Markets

Here's Why Xenoport's Shares Are Surging Today

What : Shares of Xenoport , a biopharma specializing in developing treatments forneurological disorders, saw its share rise by as much as 36% today on heavy volume. This spike in share price coincides with Xenoport announcing that its longtime CEORonald Barrett was stepping down, its workforce would be reduced, and it plans to seek a partner to further the clinical development for its development stage assets to allow the company to focus on the commercialization of itsrestless legs syndrome drug Horizant.

: Xenoport's lead experimental candidate,XP23829, has reportedly been linked togastrointestinal side effects that cast doubt on the wisdom of pushing the drug into a costly late-stage trial. By cutting its clinical program short and reorganizing its workforce, the company should be able to drastically lower its cash burn moving forward.

So what

Now what : The good news is that Horizant's sales have been growing steadily in recent quarters, and the Street expects this trend to continue next year with another 58% rise in year over year sales. So with the company essentially off-loading its clinical program for the moment, it's not out of the question for Xenoport to transition into a cash flow positive operation by as early as 2017. Having said that, I'm content to watch this small-cap biopharma from the sidelines for the time being, given that any future value creation looks to be highly dependent on a single product following this reorganization.

The next billion-dollar iSecret

The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .

The article Here's Why Xenoport's Shares Are Surging Today originally appeared on Fool.com.

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .

Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Stocks

Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More